title: Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: the United Kingdom Named Patient Programme.
abstract: BACKGROUND
  Afatinib prolongs progression-free survival (PFS) in patients with non-small cell lung cancer (NSCLC) who were previously sensitive to erlotinib or gefitinib. This study investigated experience of afatinib under a Named Patient Use (NPU) programme.
  
  
  METHODS
  Retrospective data for 63 patients were collected, including demographics, dose, toxicity and clinical efficacy.
  
  
  RESULTS
  Response rate and median PFS were 14.3% and 2.6months, respectively. Diarrhoea and rash were the most common toxicities; 46% of patients required a dose reduction and 41% had a dose delay.
  
  
  CONCLUSIONS
  Efficacy and safety in the NPU programme are consistent with the LUX-Lung 1 trial.
authors.affiliation: Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield S10 2SJ, United Kingdom.
authors.forename: F
authors.initials: F
authors.lastname: Khan
authors.affiliation: Southampton NIHR Experimental Cancer Medicine Center and Southampton University Hospitals NHS Foundation, Southampton SO16 6YD, United Kingdom.
authors.forename: C
authors.initials: C
authors.lastname: Ottensmeier
authors.affiliation: Royal Marsden Hospital, London SW3 6JJ, United Kingdom.
authors.forename: S
authors.initials: S
authors.lastname: Popat
authors.affiliation: Guy's and St. Thomas' NHS Foundation Trust, London SE1 9RT, United Kingdom.
authors.forename: D
authors.initials: D
authors.lastname: Dua
authors.affiliation: Royal Devon and Exeter NHS Foundation Trust, Exeter EX2 5DW, United Kingdom.
authors.forename: N
authors.initials: N
authors.lastname: Dorey
authors.affiliation: Royal Bournemouth Hospital, Bournemouth BH7 7DW, United Kingdom.
authors.forename: S
authors.initials: S
authors.lastname: Ellis
authors.affiliation: Southampton NIHR Experimental Cancer Medicine Center and Southampton University Hospitals NHS Foundation, Southampton SO16 6YD, United Kingdom.
authors.forename: M
authors.initials: M
authors.lastname: Szabo
authors.affiliation: Hull and East Yorkshire Hospitals NHS Trust, Hull HU16 5JQ, United Kingdom.
authors.forename: S
authors.initials: S
authors.lastname: Upadhyay
authors.affiliation: Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester M20 4BX, United Kingdom.
authors.forename: R
authors.initials: R
authors.lastname: Califano
authors.affiliation: Harrogate and District NHS Foundation Trust, Harrogate HG2 7SX, United Kingdom.
authors.forename: S
authors.initials: S
authors.lastname: Chan
authors.affiliation: Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester M20 4BX, United Kingdom.
authors.forename: L
authors.initials: L
authors.lastname: Lee
authors.affiliation: Beatson West of Scotland Cancer Centre, Glasgow G12 0YN, United Kingdom.
authors.forename: C W
authors.initials: CW
authors.lastname: Ali
authors.affiliation: Aberdeen Royal Infirmary, Aberdeen AB25 2ZN, United Kingdom.
authors.forename: M
authors.initials: M
authors.lastname: Nicolson
authors.affiliation: Southampton NIHR Experimental Cancer Medicine Center and Southampton University Hospitals NHS Foundation, Southampton SO16 6YD, United Kingdom.
authors.forename: A T
authors.initials: AT
authors.lastname: Bates
authors.affiliation: Velindre Cancer Centre, Cardiff CF14 2TL, United Kingdom.
authors.forename: M
authors.initials: M
authors.lastname: Button
authors.affiliation: United Lincolnshire Hospitals NHS Trust, Lincoln LN2 5QY, United Kingdom.
authors.forename: A
authors.initials: A
authors.lastname: Chaudhuri
authors.affiliation: Newcastle upon Tyne NHS Foundation Trust, Newcastle NE7 7DN, United Kingdom.
authors.forename: P
authors.initials: P
authors.lastname: Mulvenna
authors.affiliation: University College London Hospitals NHS Foundation Trust, London NW1 2PG, United Kingdom.
authors.forename: H M
authors.initials: HM
authors.lastname: Shaw
authors.affiliation: Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield S10 2SJ, United Kingdom. Electronic address: s.danson@sheffield.ac.uk.
authors.forename: S J
authors.initials: SJ
authors.lastname: Danson
mesh_terms: D000328:Adult; D000077716:Afatinib; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics / Q000401:mortality / Q000473:pathology; D018572:Disease-Free Survival; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009154:Mutation; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011799:Quinazolines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome; D006113:United Kingdom
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000077716:Afatinib; C512478:EGFR protein, human; D066246:ErbB Receptors
keywords: Afatinib; EGFR; Non-small cell lung cancer